Madrigal Pharmaceuticals, Inc.
Every calculator, already run for MDGL
Open the full toolkit →You have the numbers on MDGL. Get the argument.
A written report on which of these readings actually decide the outcome for Madrigal Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering MDGLAnalyst Price Target Disagreement for Madrigal Pharmaceuticals, Inc.
Wall Street's bull case implies +81% from the current price; the bear case implies +2%. A 79% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MDGL
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
MDGL — frequently asked
Is MDGL a buy right now?
Wall Street's consensus rating on Madrigal Pharmaceuticals, Inc. is Strong Buy across 17 analysts, with a mean price target of $678.06 (+28% vs. the current $531.52). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is MDGL's next earnings date?
Madrigal Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 4, 2026. A full MDGL research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Madrigal Pharmaceuticals, Inc.?
Analysts covering Madrigal Pharmaceuticals, Inc. (MDGL) range from a bear-case target of $543.00 to a bull-case high of $962.00, with a mean consensus target of $678.06 across 16 analysts. The spread of $419.00 (79% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Madrigal Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Madrigal Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MDGL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Madrigal Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.